The Medicines Discovery Catapult aims to help UK SME biotechs, academics and innovators have access to the laboratory facilities, knowledge, data, technologies and networks they need in order to progress the research and development of their programmes of medicine. Their objective is to work collaboratively as part of a syndicate to bring new proven therapies to patients in a faster and more cost-effective way.

XenoGesis has been selected as one of the CROs chosen for the partnerships by the Medicines Discovery Catapult to support its virtual R&D discovery services platform worldwide.

The Catapult’s partnerships aim is to boost UK life sciences R&D and international competitiveness by channelling high-quality projects through best-in-class service providers.

Talk to a scientist

If you’d like to get in touch with one of our scientists, please click here!